Drug Profile
CORVax 12
Alternative Names: CORVax-12Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator OncoSec Medical
- Class COVID-19 vaccines; DNA vaccines; Peptides; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in USA (IM)
- 28 Dec 2022 Providence Health & Services in collaboration with OncoSec Medical completes a phase I trial in COVID-2029 (Prevention) in the USA (NCT04627675)
- 27 Jan 2021 Phase-I clinical trials in COVID-2019 infections (Prevention) in USA (IM) (NCT04627675)